Given the 2024 changes in vitamin D recommendations for the general population, it’s reasonable to ask:
What does this mean for people living with chronic kidney disease (CKD)?
As I discussed in Part 2 of my Vitamin D Controversy series, individuals with CKD may require higher vitamin D intake and 25(OH)D levels to achieve the same active vitamin D (1,25(OH)₂D) levels as the general population.
To explore this further, let’s take a closer look at a recent consensus statement:
Are the Kidneys the Only Site of Vitamin D Metabolism?
The kidneys play a central role in converting vitamin D to its active form. However, they are not the only site.
Evidence from:
- Anephric mouse models (without kidneys)
- People post nephrectomy
suggests that extrarenal tissues can also produce active vitamin D and help maintain circulating levels.
Why this matters: Even in advanced CKD, some vitamin D activity may persist outside the kidneys.
Why Is Vitamin D Deficiency Common in CKD?
Several mechanisms contribute to low vitamin D levels in CKD:
- Reduced dietary intake
- Less sun exposure (and reduced skin synthesis)
- Increased breakdown via FGF23 (fibroblast growth factor 23)
- Losses in urine (e.g., nephrotic syndrome) or dialysate
How Often Should Vitamin D Be Monitored?
The consensus recommends measuring 25(OH)D levels:
- At initial presentation
- 3 months after changing supplementation
- Annually thereafter
Not recommended:
- 1,25(OH)₂D levels
- Free vitamin D levels
These tests have uncertain clinical value in routine care.
What Is the Target Vitamin D Level in CKD?
The authors of this paper recommend a target of:
- >75 nmol/L (>30 ng/mL)
This is higher than the 2024 Endocrine Society Guidelines and the 2011 Institute of Medicine Guidelines for the general population.
Should Vitamin D Be Supplemented in CKD?
The authors think yes—with an important caveat.
The guideline recommends supplementation to achieve >75 nmol/L, particularly in CKD stages 2–5D, to help delay secondary hyperparathyroidism (PTH elevation).
However, the evidence provided in the consensus statements is mixed:
Pre-dialysis CKD (Stages 2–5)
- 12 studies reviewed
- ~8000 IU/day typical dosing
- 8 showed ↓ PTH
- 4 showed no effect
Dialysis population
- 12 studies reviewed
- Doses between 2000–8000 IU/day
- 6 showed ↓ PTH
- 6 showed no effect
Bottom line: Vitamin D may lower PTH—but it also may not.
Does Vitamin D Improve Bone Health in CKD?
There is insufficient evidence that know one way or the other.
Key studies show:
- Fracture outcomes: A meta-analysis of vitamin D intervention trials reported too few events to draw conclusions
- A Calcium + vitamin D trial: of elderly women with Stage 1-3 CKD found a slight improvement in mineral density—but as this study included calcium supplementation too, its hard to draw firm conclusions about vitamin D specifically
- Dialysis study (5000 IU added): to standard therapy with cinacalcet and activated vitamin D reported no significant improvement in bone mineal density
Takeaway: The biologically plausible benefit has not translated into clear clinical outcomes. More studies are needed.
What About After Kidney Transplant?
The authors recommend a 25(OH)D threshold >75 nmol/L post transplant.
This was based on results from 5 studies using 1000-2000IU daily vitamin D supplementation over a 12 month period:
- 4 out of 5 studies showed reduced PTH with supplementation
However, the large VITALE trial found:
- High-dose (100,000IU monthly) vs low-dose (12,000IU monthly) vitamin D for 24 months showed no benefit for:
- Cardiovascular events
- Cancer
- Diabetes
- Mortality
- Fractures
It was safe—but not clinically impactful. One caveat to safety: The VITALE trial excluded people with hypercalcemia, so it does not provide evidence on the safety of Vitamin D supplementation in people with hypercalcemia.
The authors suggest:
- Doses may have been too low
- Follow-up (22 months) may have been too short
Both are possible—but also speculative.
My take: The VITALE study provides weak support for Vitamin D supplementation post kidney transplant.
Does Vitamin D Reduce Cardiovascular Risk or Mortality in CKD?
No. There is currently no evidence of benefit.
Ongoing trials (including a large UK dialysis study using high-dose vitamin D) may provide more clarity—but for now:
No signal of improved survival or cardiovascular outcomes.
Safety Considerations
Vitamin D is generally safe.
However, one meta-analysis found:
- Levels >75 nmol/L were associated with higher FGF23 levels
This is important because:
- Elevated FGF23 is linked to worse CKD outcomes
However:
- Its role as a clinical marker is still unclear
Bottom line: The impact of vitamin D and FGF23 requires further exploration.
Should Vitamin D Deficiency Be Treated in CKD?
Yes. Treatment is recommended.
Suggested approach:
- Use vitamin D3 (cholecalciferol) over D2
- Prefer oral supplementation
- Typical repletion:
- 5000–7000 IU/day for ~12 weeks
- Then ~2000 IU/day maintenance
- Adjust based on levels
- Avoid large single doses (>100,000 IU)
What Vitamin D Level Is Too High?
- 150–200 nmol/L: Consider holding supplementation
This threshold is higher than in the general population (~120 nmol/L), likely reflecting altered metabolism in CKD.
Key Takeaways
- Vitamin D deficiency is common in CKD and should be treated
- Supplementation may help reduce PTH levels, but results are inconsistent
- There is no strong evidence for benefit on:
- Bone health
- Cardiovascular outcomes
- Mortality
- Safety at higher vitamin D levels—especially related to FGF23—remains uncertain
Final Thoughts
Vitamin D in CKD is a classic example of:
- Strong biological rationale
- Weak and inconsistent clinical evidence
While guidelines recommend targeting higher vitamin D levels, the data supporting meaningful patient outcomes remain limited.
For clinicians, this reinforces the need to:
- Focus on patient-centered outcomes, not just lab values
- Be cautious about extrapolating benefits
- Stay open to evolving evidence
